A detailed history of Sbi Securities Co., Ltd. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 61 shares of TCRX stock, worth $147. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61
Holding current value
$147
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 05, 2025

BUY
$2.93 - $5.94 $178 - $362
61 New
61 $185,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $45.6M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Sbi Securities Co., Ltd. Portfolio

Follow Sbi Securities Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sbi Securities Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sbi Securities Co., Ltd. with notifications on news.